Pocapavir Explained

Drug Name:	Pocapavir
C:	21
H:	17
Cl:	3
O:	3
Iupac Name:	1,3-dichloro-2-benzene
Cas Number:	146949-21-5
Chembl:	CHEMBL1235858
Drugbank:	DB17736
Pubchem:	1455
Unii:	4ILA3VOV97
Smiles:	COC1=CC(=C(C=C1)OCC2=CC=C(C=C2)COC3=C(C=CC=C3Cl)Cl)Cl
Stdinchi:	1S/C21H17Cl3O3/c1-25-16-9-10-20(19(24)11-16)26-12-14-5-7-15(8-6-14)13-27-21-17(22)3-2-4-18(21)23/h2-11H,12-13H2,1H3
Stdinchikey:	XXMDDBVNWRWNCW-UHFFFAOYSA-N
Synonyms:	V-073

}

Pocapavir (V-073, SCH48973) is an antiviral drug which acts as a capsid inhibitor. It was developed for the treatment of enterovirus infections, including diseases such as polio and coxsackievirus, and also has activity against parechoviruses.^{[1] [2] [3] [4] [5] [6] [7] [8] [9]}

See also

• Pleconaril
• Rupintrivir

Notes and References

1. Lentz KN, Smith AD, Geisler SC, Cox S, Buontempo P, Skelton A, DeMartino J, Rozhon E, Schwartz J, Girijavallabhan V, O'Connell J, Arnold E . Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of three poliovirus serotypes . Structure . 5 . 7 . 961–978 . July 1997 . 9261087 . 10.1016/s0969-2126(97)00249-9 .
2. De Palma AM, Pürstinger G, Wimmer E, Patick AK, Andries K, Rombaut B, De Clercq E, Neyts J . Potential use of antiviral agents in polio eradication . Emerging Infectious Diseases . 14 . 4 . 545–551 . April 2008 . 18394270 . 10.3201/eid1404.070439 . 2570929 .
3. McKinlay MA, Collett MS, Hincks JR, Oberste MS, Pallansch MA, Okayasu H, Sutter RW, Modlin JF, Dowdle WR . Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication . The Journal of Infectious Diseases . 210 . S447–S453 . November 2014 . 25316866 . 10.1093/infdis/jiu043 .
4. Torres-Torres S, Myers AL, Klatte JM, Rhoden EE, Oberste MS, Collett MS, McCulloh RJ . First use of investigational antiviral drug pocapavir (v-073) for treating neonatal enteroviral sepsis . The Pediatric Infectious Disease Journal . 34 . 1 . 52–54 . January 2015 . 25229269 . 10.1097/INF.0000000000000497 .
5. Collett MS, Hincks JR, Benschop K, Duizer E, van der Avoort H, Rhoden E, Liu H, Oberste MS, McKinlay MA, Hartford M . Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model . The Journal of Infectious Diseases . 215 . 3 . 335–343 . February 2017 . 27932608 . 10.1093/infdis/jiw542 . 5393058 .
6. Harik N, DeBiasi RL . Neonatal nonpolio enterovirus and parechovirus infections . Seminars in Perinatology . 42 . 3 . 191–197 . April 2018 . 29526382 . 10.1053/j.semperi.2018.02.007 .
7. Copelyn J, Hincks JR, Wilmshurst JM, Petersen W, Howard W, Jallow S, Moonsamy S, Seakamela L, Suchard M, Collett MS, Eley B . Clearance of Immunodeficiency-associated Vaccine-derived Poliovirus Infection With Pocapavir . The Pediatric Infectious Disease Journal . 39 . 5 . 435–437 . May 2020 . 32150007 . 10.1097/INF.0000000000002584 .
8. Kankam MK, Burns JM, Collett MS, Corrado ML, Hincks JR . A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers . Antimicrobial Agents and Chemotherapy . 65 . 10 . e0102921 . September 2021 . 34370575 . 10.1128/AAC.01029-21 . 8448163 .
9. Tomatis Souverbielle C, Erdem G, Sánchez PJ . Update on nonpolio enterovirus and parechovirus infections in neonates and young infants . Current Opinion in Pediatrics . 35 . 3 . 380–389 . June 2023 . 36876331 . 10.1097/MOP.0000000000001236 .